Table 2. Data regarding treatment and follow-up of patients diagnosed with sacrococcygeal teratoma treated surgically from 2004 to 2019, compared by reference center.
| Variables | Reference center for fetal and obstetric risk n=18 n(%) | Reference cancer center n=7 n(%) | p-value | |
|---|---|---|---|---|
| Surgical approach | Perineal | 17 (94.4%) | 6 (85.7%) | 0.920 |
| Abdominal-Perineal | 1 (5.6%) | 1 (14.3%) | ||
| Histopathological Report | Mature Teratoma | 13 (72.2%) | 2 (28.6%) | 0.007 |
| Immature Teratoma | 1 (5.6%) | 0 (0.0%) | ||
| Malignant Teratoma* | 4 (22.2%) | 5 (71.4%) | ||
| Adjuvant Chemotherapy | Yes | 0 (0.0%) | 2 (28.6%) | 0.123 |
| Post-surgery Complications | No Complications | 10 (55.6%) | 2 (28.6%) | 0.078 |
| Infection | 0 (0.0%) | 1 (14.3%) | ||
| Dehiscence) | 4 (22.2%) | 0 (0.0%) | ||
| Infection + Dehiscence | 4 (22.2%) | 4 (57.1%) | ||
| Alpha-fetoprotein (AFP) Post-Surgery | Not Altered | 15 (83.3%) | 6 (85.7%) | 0.647 |
| Altered | 3 (16.7%) | 1 (14.3%) | ||
| Rectal exam | Normal | 5 (27.8%) | 7 (100.0%) | 0.005 |
| Not Performed | 13 (72.2%) | 0 (0.0%) | ||
| Post-surgery Tests | USG | 12 (66.6%) | 3 (42.9%) | 0.004 |
| CT | 3 (16.7%) | 0 (0.0%) | ||
| CT + USG | 0 (0.0%) | 4 (57.1%) | ||
| Not Performed | 3 (16.7%) | 0 (0.0%) | ||
| Surgery Sequelae | Yes1,2 | 4 (22.2%) | 2 (28.6%) | 0.644 |
| No | 12 (66.7%) | 5 (71.4%) | ||
| No Information | 2 (11.1%) | 0 (0.0%) | ||
| Outcome | Alive without disease | 6 (33.3%) | 4 (57.1%) | 0.022 |
| Alive with disease | 0 (0.0%) | 1 (14.3%) | ||
| Referred to another hospital | 1 (5.6%) | 0 (0.0%) | ||
| Loss of follow-up | 5 (27.8%) | 0 (0.0%) | ||
| Outpatient discharge | 6 (33.3%) | 0 (0.0%) | ||
| Death** | 0 (0.0%) | 2 (28.6%) | ||
CT: computed tomography; MR: magnetic resonance; USG: ultrasound. 1Reference center for fetal and obstetric risk: Sacral Dimple (3); PilonidalCyst (1); Myelomeningocele (2); SpinaBifida (1). 2Reference cancer center: Sacral Dimple (1); Meningocele (1).